AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17443132 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Placebo (P+P)
Number of subjects: 6
Study 15880649 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic fundus-first dissection
Number of subjects: 80
Study 15880649 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery dissection from the triangle of Calot
Number of subjects: 80
Study 12519109 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted vaginal hysterectomy
Number of subjects: 90
Study 12519109 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 90
Study 12519109 — intervention group
Group type: COMPARATOR
Intervention: Vaginal hysterectomy
Number of subjects: 90
Study 9686324 — intervention group
Group type: EXPERIMENTAL
Intervention: BT563 (10 mg/d from day 0 until day 12)
Number of subjects: 40
Study 9686324 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 40
Study 8004363 — intervention group
Group type: EXPERIMENTAL
Intervention: ket 1 mg/kg + mid 0.1 mg/kg, max. 5 mg
Number of subjects: 33
Study 8004363 — intervention group
Group type: EXPERIMENTAL
Intervention: ket 1 mg/kg + mid 0.05 mg/kg, max. 2.5 mg
Number of subjects: 33
Study 8004363 — intervention group
Group type: EXPERIMENTAL
Intervention: ket 0.75 mg/kg + mid 0.1 mg/kg, max. 5 mg
Number of subjects: 33
Study 2806201 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml dairy cream and 23 g protein (casein)
Number of subjects: 15
Study 2806201 — intervention group
Group type: COMPARATOR
Intervention: 100 ml dairy cream
Number of subjects: 15
Study 2806201 — intervention group
Group type: EXPERIMENTAL
Intervention: 23 g casein
Number of subjects: 15
Study 1105777 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuine roentgen radiation treatment
Number of subjects: 104
Study 1105777 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (placebo)
Number of subjects: 104
Study 28718904 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous serum drops
Number of subjects: 60
Study 28718904 — intervention group
Group type: COMPARATOR
Intervention: Conventional artificial tears
Number of subjects: 60
Study 28718904 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study 27505329 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm: invitation to clinical examination followed by ambulant ECG recording
Number of subjects: 2443
Study 27505329 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-participants)
Number of subjects: 2443
Study 25908360 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for calculating maximum dose of local anaesthetic
Number of subjects: 0
Study 25908360 — intervention group
Group type: COMPARATOR
Intervention: Standard mathematical techniques for drafting the nomogram
Number of subjects: 0
Study 23142857 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education intervention (PEI)
Number of subjects: 0
Study 23142857 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 0
Study 20431490 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic assessment by Observer A
Number of subjects: 80
Study 20431490 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic assessment by Observer B
Number of subjects: 80
Study 20431490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver reproducibility for Observer A
Number of subjects: 80
Study 20431490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver reproducibility for Observer B
Number of subjects: 80
Study 18371578 — intervention group
Group type: EXPERIMENTAL
Intervention: Explanatory models of addictive behaviour among native German and Russian-German youth
Number of subjects: 268
Study 18371578 — intervention group
Group type: COMPARATOR
Intervention: Explanatory models of addictive behaviour among Turkish youth
Number of subjects: 268
Study 16755298 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (lap), 452 patients
Number of subjects: 682
Study 16755298 — intervention group
Group type: COMPARATOR
Intervention: Open procedure (open), 230 patients
Number of subjects: 682
Study 14629776 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based strategies to develop broader family and community supports for recent mothers.
Number of subjects: 5740
Study 14629776 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care strategies to increase practitioners' response to maternal depression and physical health issues.
Number of subjects: 5740
Study 14629776 — intervention group
Group type: COMPARATOR
Intervention: Comparison arm (control group).
Number of subjects: 5740
Study 11029598 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-inhibition (quinapril, 10 mg day-1)
Number of subjects: 47
Study 11029598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 9313070 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniocentesis
Number of subjects: 5085
Study 9313070 — intervention group
Group type: COMPARATOR
Intervention: Standard amniocentesis
Number of subjects: 5085
Study 8393028 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 2 mg
Number of subjects: 10
Study 8393028 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg
Number of subjects: 10
Study 8393028 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 8 mg
Number of subjects: 10
Study 8393028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3772621 — intervention group
Group type: EXPERIMENTAL
Intervention: Seminar method
Number of subjects: 46
Study 3772621 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 2492746 — intervention group
Group type: EXPERIMENTAL
Intervention: + (milk containing lactose)
Number of subjects: 15
Study 2492746 — intervention group
Group type: COMPARATOR
Intervention: - (milk containing glucose)
Number of subjects: 15
Study 2492746 — intervention group
Group type: COMPARATOR
Intervention: Water solution
Number of subjects: 15
Study 30947938 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-Eluting Stent (EES)
Number of subjects: 2667
Study 30947938 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-Eluting Stent (SES)
Number of subjects: 2667
Study 27632067 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA)
Number of subjects: 102
Study 27632067 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid (CS)
Number of subjects: 102
Study 27632067 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer Solution (LR; placebo)
Number of subjects: 102
Study 26193719 — intervention group
Group type: EXPERIMENTAL
Intervention: He-wei Jie-gu decoction and Caltrate D
Number of subjects: 90
Study 26193719 — intervention group
Group type: COMPARATOR
Intervention: Caltrate D
Number of subjects: 90
Study 24192120 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker (CCB)
Number of subjects: 265
Study 24192120 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blocker (ARB)
Number of subjects: 265
Study 24192120 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting enzyme inhibitor (ACEI)
Number of subjects: 265
Study 24192120 — intervention group
Group type: COMPARATOR
Intervention: Control group (valsartan or amlodipine)
Number of subjects: 265
Study 22093311 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg, s.c., 12 hours before and after surgery, then once daily for 7 consecutive days)
Number of subjects: 1928
Study 22093311 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1928
Study 22093311 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg, s.c.)
Number of subjects: 1928
Study 20092769 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential fusion
Number of subjects: 437
Study 20092769 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral fusion
Number of subjects: 437
Study 16707508 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient completed agenda form
Number of subjects: 976
Study 16707508 — intervention group
Group type: EXPERIMENTAL
Intervention: Education for general practitioners
Number of subjects: 976
Study 16707508 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (agenda form and education)
Number of subjects: 976
Study 16707508 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 976
Study 14636907 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (ACE inhibitor)
Number of subjects: 0
Study 14636907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14636907 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR >/=90 ml/min/1.73 m(2)
Number of subjects: 0
Study 14636907 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematocrit >/=36%
Number of subjects: 0
Study 14636907 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest hematocrit-GFR risk class (hematocrit >/=36%, GFR >/=90 ml/min/1.73 m(2))
Number of subjects: 0
Study 14636907 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest risk class (hematocrit <33%, GFR <60 ml/min/1.73 m(2))
Number of subjects: 0
Study 10578020 — intervention group
Group type: EXPERIMENTAL
Intervention: OKG (20g OKG/d)
Number of subjects: 14
Study 10578020 — intervention group
Group type: COMPARATOR
Intervention: Control (Two Cal HN, 1.4 times BEE calories)
Number of subjects: 14
Study 7812924 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG prophylactic therapy (40 mg monthly for 12 times) - Group A
Number of subjects: 138
Study 7812924 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group - Group B
Number of subjects: 138
Study 2013661 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluff pulp and superabsorbent materials in various pad types
Number of subjects: 45
Study 2013661 — intervention group
Group type: EXPERIMENTAL
Intervention: Superabsorbent material
Number of subjects: 45
Study 2013661 — intervention group
Group type: EXPERIMENTAL
Intervention: Securing the pad with appropriate net pants
Number of subjects: 45
Study 7174304 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 245
Study 7174304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 31540014 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular gluten-free diet (R-GFD)
Number of subjects: 46
Study 31540014 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-FODMAP gluten-free diet (LF-GFD)
Number of subjects: 46
Study 28877896 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium- and magnesium-enriched salt (K/Mg salt)
Number of subjects: 291
Study 28877896 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-enriched salt (K salt)
Number of subjects: 291
Study 28877896 — intervention group
Group type: COMPARATOR
Intervention: Regular salt (Na salt)
Number of subjects: 291
Study 26735058 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy with a pulsed wave form, visible ray, wave length of 632.8 nm, 30 mW peak power, applied for 80 seconds (4J/cm2), 12 appointments (3 weekly in alternated days)
Number of subjects: 16
Study 26735058 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 16
Study 24210208 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents recorded their child's micturition using a video camera.
Number of subjects: 30
Study 24210208 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents were told to have their child drink enough fluids and come with a full bladder.
Number of subjects: 30
Study 24210208 — intervention group
Group type: COMPARATOR
Intervention: Control group where parents were not given any follow-up visit direction.
Number of subjects: 30
Study 21505146 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 8
Study 21505146 — intervention group
Group type: COMPARATOR
Intervention: Control (nonobese subjects)
Number of subjects: 8
Study 18465723 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved levobunolol
Number of subjects: 27
Study 18465723 — intervention group
Group type: COMPARATOR
Intervention: Unpreserved levobunolol
Number of subjects: 27
Study 16861077 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon/Epiphany
Number of subjects: 96
Study 16861077 — intervention group
Group type: EXPERIMENTAL
Intervention: gutta‐percha/Roth (set for 3 weeks)
Number of subjects: 96
Study 16861077 — intervention group
Group type: EXPERIMENTAL
Intervention: gutta‐percha/Roth
Number of subjects: 96
Study 16861077 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon/Epiphany (single cone)
Number of subjects: 96
Study 16861077 — intervention group
Group type: COMPARATOR
Intervention: Resilon cones without primer/sealer (positive control)
Number of subjects: 96
Study 16861077 — intervention group
Group type: EXPERIMENTAL
Intervention: gutta‐percha/AH Plus
Number of subjects: 96
Study 16861077 — intervention group
Group type: EXPERIMENTAL
Intervention: gutta‐percha/AH Plus (set for 8 hours)
Number of subjects: 96
Study 16861077 — intervention group
Group type: COMPARATOR
Intervention: Nail varnish sealing (negative control)
Number of subjects: 96
Study 14553869 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline‐rifampin-coated catheters
Number of subjects: 130
Study 14553869 — intervention group
Group type: COMPARATOR
Intervention: Unimpregnated catheters
Number of subjects: 130
Study 10910851 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 20 microg
Number of subjects: 46
Study 10910851 — intervention group
Group type: COMPARATOR
Intervention: Epidural fentanyl 100 microg
Number of subjects: 46
Study 8757204 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin 1 microgram
Number of subjects: 0
Study 8757204 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin 10 micrograms
Number of subjects: 0
Study 8757204 — intervention group
Group type: EXPERIMENTAL
Intervention: African American race
Number of subjects: 0
Study 8757204 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 0
Study 1333708 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 20
Study 1333708 — intervention group
Group type: COMPARATOR
Intervention: Teturam
Number of subjects: 20
Study 6384377 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 545
Study 6384377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 545
Study 29772945 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterocervical angle (UCA) ≥97.5°
Number of subjects: 148
Study 29772945 — intervention group
Group type: COMPARATOR
Intervention: Uterocervical angle (UCA) <97.5°
Number of subjects: 148
Study 29772945 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterocervical angle (UCA)
Number of subjects: 148
Study 31331137 — intervention group
Group type: EXPERIMENTAL
Intervention: Hetero‐Bevacizumab
Number of subjects: 111
Study 31331137 — intervention group
Group type: COMPARATOR
Intervention: Reference Bevacizumab (RMP)
Number of subjects: 111
Study 28169916 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg E4
Number of subjects: 49
Study 28169916 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg E4
Number of subjects: 49
Study 28169916 — intervention group
Group type: COMPARATOR
Intervention: 2 mg E2V
Number of subjects: 49
Study 26224299 — intervention group
Group type: EXPERIMENTAL
Intervention: Food, Activity, and Breastfeeding (FAB) intervention; Combination (FAB and Sleep)
Number of subjects: 802
Study 26224299 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep intervention; Combination (FAB and Sleep)
Number of subjects: 802
Study 26224299 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 802
Study 26224299 — intervention group
Group type: COMPARATOR
Intervention: Sleep
Number of subjects: 802
Study 24472479 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT (standard chemotherapy)
Number of subjects: 680
Study 24472479 — intervention group
Group type: COMPARATOR
Intervention: Off-trial (standard chemotherapy)
Number of subjects: 680
Study 21114776 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium gluconate 1g + 15% magnesium sulphate 1g diluted in 100 mL of dextrose 5%
Number of subjects: 27
Study 21114776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 18080748 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy with CMF (cyclophosphamide, methotrexate, fluorouracil; 600/40/600 mg/m(2))
Number of subjects: 423
Study 18080748 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemotherapy (CMF or EC depending on node status)
Number of subjects: 423
Study 16534210 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweeping of membranes
Number of subjects: 101
Study 16534210 — intervention group
Group type: COMPARATOR
Intervention: Control (no sweeping)
Number of subjects: 101
Study 15015909 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-based sessions
Number of subjects: 12
Study 15015909 — intervention group
Group type: COMPARATOR
Intervention: Play-based sessions
Number of subjects: 12
Study 11126468 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic women
Number of subjects: 38
Study 11126468 — intervention group
Group type: COMPARATOR
Intervention: Anglo women
Number of subjects: 38
Study 9343270 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (0.4 mg/day)
Number of subjects: 28
Study 8238327 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 g AA.kg LBM‐1.day‐1
Number of subjects: 6
Study 8238327 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g AA.kg LBM‐1.day‐1
Number of subjects: 6
Study 8238327 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g AA.kg LBM‐1.day‐1
Number of subjects: 6
Study 2862898 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam 20 mg
Number of subjects: 16
Study 2862898 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam 6 mg
Number of subjects: 16
Study 2862898 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 16
Study 2862898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29755054 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of Community Health Workers (CHWs)
Number of subjects: 15
Study 26964730 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg/d
Number of subjects: 59
Study 26964730 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (in db/db mice)
Number of subjects: 59
Study 26964730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 26964730 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (in db/db mice)
Number of subjects: 59
Study 25299442 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy followed by rehabilitation exercises
Number of subjects: 30
Study 25299442 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy alone
Number of subjects: 30
Study 25299442 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation exercises alone
Number of subjects: 30
Study 21742443 — intervention group
Group type: EXPERIMENTAL
Intervention: Chestnut tannins 10 g/kg diet (CT10)
Number of subjects: 4
Study 21742443 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 4
Study 21742443 — intervention group
Group type: EXPERIMENTAL
Intervention: Chestnut tannins 5 g/kg diet (CT5)
Number of subjects: 4
Study 21742443 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet (N)
Number of subjects: 4
Study 21189196 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel lifts of 6 mm
Number of subjects: 24
Study 21189196 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel lifts of 9 mm
Number of subjects: 24
Study 21189196 — intervention group
Group type: COMPARATOR
Intervention: Athletic shoes alone
Number of subjects: 24
Study 18402729 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride, a potent 5 alpha‐reductase inhibitor, measured in human plasma
Number of subjects: 0
Study 16192529 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 228
Study 16192529 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release naproxen sodium 1100 mg
Number of subjects: 228
Study 16192529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 12614467 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha‐2b 5 MU daily for 4 weeks followed by IFN (5 MU tiw) and ribavirin (1000‐1200 mg/day) for 48 weeks (Group A)
Number of subjects: 119
Study 12614467 — intervention group
Group type: COMPARATOR
Intervention: IFN alpha‐2b 5 MU tiw for 4 weeks followed by IFN (5 MU tiw) and ribavirin (1000‐1200 mg/day) for 48 weeks (Group B)
Number of subjects: 119
Study 12614467 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall SVR in patients with genotype 1 or 4
Number of subjects: 119
Study 12614467 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall SVR in patients with genotype 2 or 3
Number of subjects: 119
Study 10539121 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 164
Study 10539121 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 164
Study 7977921 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse assessment visit and follow‐up interventions targeting risk factors for disability and falls (group 1, n = 635)
Number of subjects: 1559
Study 7977921 — intervention group
Group type: EXPERIMENTAL
Intervention: General health promotion nurse visit (group 2, n = 317)
Number of subjects: 1559
Study 7977921 — intervention group
Group type: COMPARATOR
Intervention: Usual care (group 3, n = 607)
Number of subjects: 1559
Study 2508167 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 8
Study 2508167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine infusion (40 mg)
Number of subjects: 8
Study 2508167 — intervention group
Group type: COMPARATOR
Intervention: Instructed placebo (saline infusion with prior instruction)
Number of subjects: 8
Study 2508167 — intervention group
Group type: COMPARATOR
Intervention: Initial placebo session
Number of subjects: 8
Study 184309 — intervention group
Group type: EXPERIMENTAL
Intervention: DBcAMP infusion at 10 mg/min for 20 min
Number of subjects: 10
Study 184309 — intervention group
Group type: EXPERIMENTAL
Intervention: DBcAMP infusion at 20 mg/min for 20 min
Number of subjects: 10